dihydrobetulinic acid: structure given in first source
dihydrobetulinic acid : A pentacyclic triterpenoid that is lupane having a 3beta-hydroxy and 28-carboxy substituents. Isolated from the leaves of Syzygium claviflorum, it exhibits anti-HIV and antileishmanial activity.
Flora | Rank | Flora Definition | Family | Family Definition |
---|---|---|---|---|
Syzygium claviflorum | species | [no description available] | Myrtaceae | The myrtle plant family of the order Myrtales. It includes several aromatic medicinal plants such as EUCALYPTUS.[MeSH] |
ID Source | ID |
---|---|
PubMed CID | 65319 |
CHEMBL ID | 37 |
CHEBI ID | 65485 |
SCHEMBL ID | 3781854 |
MeSH ID | M0259077 |
Synonym |
---|
chembl37 |
bdbm50050950 |
3-hydroxylupan-28-oic acid, (3.beta.) |
(1s,3as,5ar,5br,7ar,9s,11ar,11br,13ar,13br)-9-hydroxy-1-isopropyl-5a,5b,8,8,11a-pentamethyl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysene-3a-carboxylic acid |
25488-53-3 |
dihydrobetulinic acid |
(1s,3as,5ar,5br,7ar,9s,11ar,11br,13ar,13br)-9-hydroxy-5a,5b,8,8,11a-pentamethyl-1-propan-2-yl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysene-3a-carboxylic acid |
SCHEMBL3781854 |
(3beta)-3-hydroxylupan-28-oic acid |
lupan-28-oic acid, 3-hydroxy-, (3beta)- |
CHEBI:65485 |
20,29-dihydrobetulinic acid |
PZXJOHSZQAEJFE-FZFNOLFKSA-N |
(1s,3as,5ar,5br,7ar,9s,11ar,11br,13ar,13br)-9-hydroxy-1-isopropyl-5a,5b,8,8,11a-pentamethylicosahydro-1h-cyclopenta[a]chrysene-3a-carboxylic acid |
Q27133928 |
DTXSID40948376 |
3-hydroxylupan-28-oic acid |
AKOS040751573 |
Role | Description |
---|---|
metabolite | Any intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites. |
anti-HIV agent | An antiviral agent that destroys or inhibits the replication of the human immunodeficiency virus. |
antileishmanial agent | An antiprotozoal drug used to treat or prevent infections caused by protozoan parasites that belong to the genus Leishmania. |
EC 5.99.1.2 (DNA topoisomerase) inhibitor | A topoisomerase inhibitor that inhibits the bacterial enzymes of the DNA topoisomerases, Type I class (EC 5.99.1.2) that catalyze ATP-independent breakage of one of the two strands of DNA, passage of the unbroken strand through the break, and rejoining of the broken strand. These bacterial enzymes reduce the topological stress in the DNA structure by relaxing negatively, but not positively, supercoiled DNA. |
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor | A topoisomerase inhibitor that inhibits DNA topoisomerase (ATP-hydrolysing), EC 5.99.1.3 (also known as topoisomerase II and as DNA gyrase), which catalyses ATP-dependent breakage of both strands of DNA, passage of the unbroken strands through the breaks, and rejoining of the broken strands. |
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Class | Description |
---|---|
hydroxy monocarboxylic acid | Any monocarboxylic acid which also contains a separate (alcoholic or phenolic) hydroxy substituent. |
pentacyclic triterpenoid | |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (40.00) | 18.2507 |
2000's | 2 (40.00) | 29.6817 |
2010's | 1 (20.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.43) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 6 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |